AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32644833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ER-MPH (0.48 mg/kg equivalent of IR-MPH)
Number of subjects: 24
Study 33015164 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention for 1 month
Number of subjects: 45
Study 33015164 — intervention group
Group type: COMPARATOR
Intervention: Standard care with antipsychotic medication
Number of subjects: 45
Study 32858606 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D personality present in 225 patients (21%)
Number of subjects: 1055
Study 32858606 — intervention group
Group type: COMPARATOR
Intervention: No Type D personality
Number of subjects: 1055
Study 32320845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-assisted intervention (SPARK) consisting of interactive games and activities to improve provider fidelity and child engagement in evidence-based psychotherapies.
Number of subjects: 0
Study 32320845 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on control intervention are not available.
Number of subjects: 0
Study 33638105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral subcostal TAPB
Number of subjects: 112
Study 33638105 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 112
Study 34526073 — intervention group
Group type: EXPERIMENTAL
Intervention: Total or partial tonsillar resection (Tonsillectomy (TE) or Tonsillotomy (TT))
Number of subjects: 285
Study 34526073 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tonsillar resection (Tonsillectomy (TE))
Number of subjects: 285
Study 34526073 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (WW)
Number of subjects: 285
Study 35804322 — intervention group
Group type: EXPERIMENTAL
Intervention: WWACP (e-health enabled health promotion intervention)
Number of subjects: 351
Study 35804322 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 351
Study 33175618 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer bandage
Number of subjects: 186
Study 33175618 — intervention group
Group type: COMPARATOR
Intervention: Four-layer bandage
Number of subjects: 186
Study 36109757 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior science-based intervention program
Number of subjects: 30
Study 36109757 — intervention group
Group type: COMPARATOR
Intervention: Usual practices (Control)
Number of subjects: 30
Study 32995974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 221
Study 32995974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoprogression (detected by iRECIST)
Number of subjects: 221
Study 32521927 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 84
Study 32521927 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 34048504 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ-CVac (5.12x10^4) administered via three direct venous inoculations (DVIs) seven days apart
Number of subjects: 15
Study 34048504 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ-CVac (1.024x10^5) administered via three direct venous inoculations (DVIs) five days apart
Number of subjects: 15
Study 34048504 — intervention group
Group type: COMPARATOR
Intervention: PfSPZ-CVac (5.12x10^4) administered via three injections five days apart (previous study)
Number of subjects: 15
Study 35358769 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 60
Study 35358769 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 60
Study 33811250 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-interferon-α (peg-IFN-α) add-on treatment
Number of subjects: 0
Study 33811250 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-interferon-α (peg-IFN-α) switch treatment
Number of subjects: 0
Study 33811250 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-interferon-α (peg-IFN-α) therapy (both add-on and switch)
Number of subjects: 0
Study 34007066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy (LiST)
Number of subjects: 102
Study 34007066 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 102
Study 33593287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile e‐learning, mentor‐led online social support networking, and monthly face‐to‐face mentoring support group meetings
Number of subjects: 140
Study 33593287 — intervention group
Group type: COMPARATOR
Intervention: 8‐h conventional lectures
Number of subjects: 140
Study 32723294 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF group (once and twice weekly HDF)
Number of subjects: 34
Study 32723294 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice HDF subgroup
Number of subjects: 34
Study 32723294 — intervention group
Group type: COMPARATOR
Intervention: Once HDF subgroup
Number of subjects: 34
Study 32723294 — intervention group
Group type: EXPERIMENTAL
Intervention: OL-HDF (once a week)
Number of subjects: 34
Study 35123450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 200
Study 35123450 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 200
Study 34826668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (Visanne) 2 mg/day
Number of subjects: 70
Study 34826668 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (Yasmin, 0.03 mg ethinyl estradiol and 3 mg drospirenone)
Number of subjects: 70
Study 34826668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest and COC
Number of subjects: 70
Study 34826668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 70
Study 33960309 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (1:1 placebo-controlled treatment)
Number of subjects: 101
Study 32672593 — intervention group
Group type: EXPERIMENTAL
Intervention: iStent Inject trabecular bypass stent (TBS) plus cataract surgery
Number of subjects: 0
Study 32672593 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery alone
Number of subjects: 0
Study 32672593 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS plus cataract surgery
Number of subjects: 0
Study 35347557 — intervention group
Group type: EXPERIMENTAL
Intervention: Predilution hemodiafiltration (HDF)
Number of subjects: 38
Study 35347557 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 38
Study 32942939 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline‐traction with restricted mouth opening (MR)
Number of subjects: 56
Study 32942939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral thrust with opening permitted (BP)
Number of subjects: 56
Study 32942939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OAs
Number of subjects: 56
Study 32942939 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both OAs)
Number of subjects: 56
Study 32942939 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of MR and BP OAs
Number of subjects: 56
Study 32942939 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline overjet measures >2.9 mm
Number of subjects: 56
Study 32942939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean and minimum SaO(2)
Number of subjects: 56
Study 32942939 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA individuals
Number of subjects: 56
Study 32394089 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-anatomy-specific rehearsal on a high-fidelity simulator prior to real angiography
Number of subjects: 40
Study 32394089 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured simulation curriculum for angiographer novices
Number of subjects: 40
Study 32394089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulation)
Number of subjects: 40
Study 34511181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatments
Number of subjects: 0
Study 34511181 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational/behavioral treatments
Number of subjects: 0
Study 34511181 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation treatments
Number of subjects: 0
Study 34511181 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 34511181 — intervention group
Group type: COMPARATOR
Intervention: Large case series
Number of subjects: 0
Study 33239406 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing for lung health (SLH)
Number of subjects: 120
Study 33239406 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 32995976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100F‐TMP‐MI Paste Plus
Number of subjects: 72
Study 32995976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 32995976 — intervention group
Group type: COMPARATOR
Intervention: 1100 ppm F (1100F)
Number of subjects: 72
Study 32995976 — intervention group
Group type: COMPARATOR
Intervention: MI Paste Plus®
Number of subjects: 72
Study 32995976 — intervention group
Group type: COMPARATOR
Intervention: 1100F + MI Paste Plus® (1100F‐MI Paste Plus)
Number of subjects: 72
Study 32995976 — intervention group
Group type: COMPARATOR
Intervention: 1100F + 3 % TMP (1100F‐TMP)
Number of subjects: 72
Study 32961242 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational determination of wheal area using a Python algorithm and smartphone photographs
Number of subjects: 20
Study 32961242 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature monitoring using an infrared temperature sensor
Number of subjects: 20
Study 35354481 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 156
Study 35354481 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Supported Prolonged Exposure (PE with family involvement)
Number of subjects: 156
Study 32942914 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mobile phone instructional text messages with standard care
Number of subjects: 79
Study 32942914 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 79
Study 32564438 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (75 mg twice daily)
Number of subjects: 0
Study 32564438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36405604 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparameter EEG-guided sedation
Number of subjects: 50
Study 36405604 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard sedation protocol)
Number of subjects: 50
Study 32578029 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy-based care (RTBC)
Number of subjects: 130
Study 32578029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 36244623 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laser group (16+0/7 to 16+6/7 weeks' gestation)
Number of subjects: 343
Study 36244623 — intervention group
Group type: COMPARATOR
Intervention: Standard laser group (≥17 weeks' gestation)
Number of subjects: 343
Study 33486869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phosphorus diet (HPD): 2300 mg/d
Number of subjects: 6
Study 32044831 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 100
Study 32044831 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 100
Study 36200646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dual-impregnated antibiotic-loaded cement (DIAC) including gentamicin and clindamycin
Number of subjects: 7000
Study 36200646 — intervention group
Group type: COMPARATOR
Intervention: Low-dose single-impregnated gentamicin antibiotic-loaded cement (SIAC)
Number of subjects: 7000
Study 33795330 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOFA) 5mg twice daily
Number of subjects: 87
Study 34519018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 20
Study 34519018 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 20
Study 34588250 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-specific Virtual Reality for Family members/relatives (ICU-VR-F)
Number of subjects: 160
Study 34588250 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 34588250 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-VR-F
Number of subjects: 160
Study 33905281 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-Focused Cognitive Behavioral Therapy (EF-CBT)
Number of subjects: 102
Study 33905281 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Mentorship Training (RMT)
Number of subjects: 102
Study 32386362 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures aimed at optimizing motor activity of students
Number of subjects: 0
Study 32386362 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological-hygienic standards of motor activity
Number of subjects: 0
Study 33631500 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg, orally once daily in the morning)
Number of subjects: 71
Study 33631500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally once daily in the morning)
Number of subjects: 71
Study 33631500 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 71
Study 33631500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 35268027 — intervention group
Group type: EXPERIMENTAL
Intervention: High NO3- (2 × 70 mL beetroot juice/day)
Number of subjects: 62
Study 35268027 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium NO3- (70 mL beetroot juice/day)
Number of subjects: 62
Study 35268027 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NO3- (70 mL beetroot juice on alternate days)
Number of subjects: 62
Study 35268027 — intervention group
Group type: COMPARATOR
Intervention: Placebo (70 mL of NO3--depleted beetroot juice on alternate days)
Number of subjects: 62
Study 33638735 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 455
Study 33638735 — intervention group
Group type: COMPARATOR
Intervention: Lenvatinib
Number of subjects: 455
Study 32209983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester drink ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate, 482 mg/kg body mass)
Number of subjects: 11
Study 32209983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 32209983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester drink
Number of subjects: 11
Study 33550228 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 120
Study 33550228 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 120
Study 33550228 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-intensity interval training and time-restricted eating
Number of subjects: 120
Study 33550228 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 33060632 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose BDP/F 100/6 two inhalations b.i.d. (n=31)
Number of subjects: 60
Study 33060632 — intervention group
Group type: COMPARATOR
Intervention: BUD/F 200/6 two inhalations b.i.d. (n=29)
Number of subjects: 60
Study 34625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational flyer and monthly HTN education messages for one year (Case group)
Number of subjects: 0
Study 34625396 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no educational intervention)
Number of subjects: 0
Study 33126100 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA) intervention
Number of subjects: 50
Study 32563496 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired left ventricle ejection fraction
Number of subjects: 0
Study 32563496 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricle global longitudinal strain (GLS)
Number of subjects: 0
Study 32563496 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic function grade
Number of subjects: 0
Study 35638702 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Acceptable Symptom State (PASS)
Number of subjects: 0
Study 35638702 — intervention group
Group type: COMPARATOR
Intervention: Latent class analysis
Number of subjects: 0
Study 34465144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 0
Study 34465144 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 36378058 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiedu granule (JDG)
Number of subjects: 62
Study 36378058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 33002791 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating And Lifestyle after Stroke (HEALS) intervention
Number of subjects: 100
Study 33002791 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 35181450 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIM setup
Number of subjects: 80
Study 34682341 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self‐fitting tool
Number of subjects: 19
Study 34682341 — intervention group
Group type: COMPARATOR
Intervention: Traditional audiological fitting
Number of subjects: 19
Study 32641137 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of residual metastatic disease +/− the primary tumor
Number of subjects: 53
Study 32641137 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical group
Number of subjects: 53
Study 34224256 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine therapy
Number of subjects: 0
Study 34224256 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32024584 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP + Behavioral Sleep Medicine (BSM) intervention targeting physical activity and eating behavior changes
Number of subjects: 60
Study 32024584 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with CPAP
Number of subjects: 60
Study 32024584 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP + BSM intervention
Number of subjects: 60
Study 34807712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive fatigue group (mentally demanding motor task)
Number of subjects: 59
Study 34807712 — intervention group
Group type: COMPARATOR
Intervention: Nonfatigued control group (undemanding motor task)
Number of subjects: 59
Study 34836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei LTL1879
Number of subjects: 20
Study 32942663 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games (AVG) combined with exercise
Number of subjects: 45
Study 32942663 — intervention group
Group type: EXPERIMENTAL
Intervention: BKOOL cycling simulator
Number of subjects: 45
Study 32942663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring Fit Adventures
Number of subjects: 45
Study 32942663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Mats
Number of subjects: 45
Study 32942663 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox Kinect
Number of subjects: 45
Study 32942663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Number of subjects: 45
Study 32942663 — intervention group
Group type: EXPERIMENTAL
Intervention: AVG combined with multi-component exercise
Number of subjects: 45
Study 35986325 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 50
Study 35986325 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 50
Study 32075817 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC (n=95)
Number of subjects: 178
Study 32075817 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=83)
Number of subjects: 178
Study 33592176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily, with dose reductions to 40 mg and 20 mg allowed)
Number of subjects: 147
Study 33592176 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg, 4 weeks on and 2 weeks off, with dose reductions to 37.5 mg and 25 mg allowed)
Number of subjects: 147
Study 33592176 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib (250 mg twice daily, with dose reductions to 200 mg twice daily and 250 mg once daily allowed)
Number of subjects: 147
Study 33592176 — intervention group
Group type: COMPARATOR
Intervention: Savolitinib (600 mg daily, with dose reductions to 400 mg and 200 mg allowed)
Number of subjects: 147
Study 32746775 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 232
Study 32746775 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 232
Study 32746775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 36464853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 18 mg/day
Number of subjects: 152
Study 36464853 — intervention group
Group type: COMPARATOR
Intervention: Lenvatinib 24 mg/day
Number of subjects: 152
Study 33588696 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative patient testimonial
Number of subjects: 167
Study 33588696 — intervention group
Group type: COMPARATOR
Intervention: Fact-based information text
Number of subjects: 167
Study 32358259 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical biometer (IOLMaster 700)
Number of subjects: 93
Study 32358259 — intervention group
Group type: COMPARATOR
Intervention: Scheimpflug device (Pentacam)
Number of subjects: 93
Study 34609378 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD) for 4 weeks
Number of subjects: 39
Study 34609378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 32807151 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (classroom lecture, pamphlet, educational text messages, educational pamphlets) conducted for 1 month in four sessions
Number of subjects: 110
Study 32807151 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 110
Study 34472020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-commitment reminder alone (1 message, mid-October)
Number of subjects: 196486
Study 34472020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-commitment + loss frame messages
Number of subjects: 196486